BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
$26.74M
Dr. Vimal D. Mehta Ph.D.
89.00
New Haven, CT
Mar 08, 2018
-0.19
$-3.46
2.06
2.35
-4,487.39%
-0.24
-0.00
-0.34
10.69
2.25
-164.79%
176.93%
Similar stocks (14)
Exelixis, Inc.
EXEL
Viking Therapeutics, Inc.
VKTX
Madrigal Pharmaceuticals, Inc.
MDGL
Apellis Pharmaceuticals, Inc.
APLS
TG Therapeutics, Inc.
TGTX
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
Amylyx Pharmaceuticals, Inc.
AMLX
Acumen Pharmaceuticals, Inc.
ABOS
X4 Pharmaceuticals, Inc.
XFOR
Elevation Oncology, Inc.
ELEV
Hepion Pharmaceuticals, Inc.
HEPA
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (13)
iShares Micro-Cap ETF
IWC
0.00442%
Schwab U.S. Small-Cap ETF
SCHA
0.0012963204%
Schwab U.S. Broad Market ETF
SCHB
9.62909e-5%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (14)
Exelixis, Inc.
EXEL
Viking Therapeutics, Inc.
VKTX
Madrigal Pharmaceuticals, Inc.
MDGL
Apellis Pharmaceuticals, Inc.
APLS
TG Therapeutics, Inc.
TGTX
Day One Biopharmaceuticals, Inc.
DAWN
Terns Pharmaceuticals, Inc.
TERN
Inozyme Pharma, Inc.
INZY
Amylyx Pharmaceuticals, Inc.
AMLX
Acumen Pharmaceuticals, Inc.
ABOS
X4 Pharmaceuticals, Inc.
XFOR
Elevation Oncology, Inc.
ELEV
Hepion Pharmaceuticals, Inc.
HEPA
eFFECTOR Therapeutics, Inc.
EFTR
ETF Exposure (13)
iShares Micro-Cap ETF
IWC
0.00442%
Schwab U.S. Small-Cap ETF
SCHA
0.0012963204%
Schwab U.S. Broad Market ETF
SCHB
9.62909e-5%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%